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A B S T R A C T
Background: Evidence-based harm reduction intervention components which might benefit pharmacy patients
have not been integrated and studied.
Objective: To investigate the feasibility and acceptability of a proposed pharmacy-based harm reduction inter-
vention to reduce opioid overdose, HIV and hepatitis C called PharmNet.
Methods: Indiana managing pharmacists were surveyed in 2018 to assess the feasibility and acceptability of an in-
tervention for opioid misuse screening, brief intervention, syringe and naloxone dispensing, and referrals provision.
The Consolidated Framework for Implementation Research informed the survey development and analysis.
Results: The sample included 303 (30.8%) pharmacists; 215 (70.9%) provided detailed written comments.
Intervention Characteristics: 83.3% believed PharmNet would benefit patients, and that staff could deliver the
intervention with adequate training (70.0%). Inner Setting: While 77.2% believed their pharmacy culture
supported practice change, 57.5% of chain pharmacists believed their pharmacies would not have time for
PharmNet. Outer Setting: 73.3% believed additional addiction and overdose screening is needed in their com-
munity, and pharmacies should offer new services to help reduce opioid overdose and addiction among their
patients (79.5%). A vast majority (97.7%) were asked by patients in the past 2 years about syringe related issues;
67.7% were asked about syringes for non-prescription injection drug use. Individuals Involved: While 62.4%
believed PharmNet was within pharmacy scope of practice and 90.1% were comfortable consulting about syr-
inge use, pharmacists reported that they had limited control over the implementation environment. Process:
38.0% of pharmacists indicated interest in advising the development of PharmNet.
Conclusions: An implementation trial of a modified version of PharmNet is likely feasible; yet will be challenged
by structural pressures particularly in chain pharmacies. Successful implementation will involve the develop-
ment of resources and policy components to manage outer and inner setting characteristics and align the in-
tervention to the implementation environment.
Introduction
Community pharmacists and pharmacies are increasingly re-
cognized as important contributors to community health access.1–4 This
is especially apparent with the opioid epidemic in the United States
(U.S.), as pharmacy-based research seeks ways of approaching
screening and/or risk assessment,5–7 opioid consultation,8–10 and na-
loxone and syringe dispensing.11,12 The need for opioid and related
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harm reduction services in pharmacies is especially acute in the U.S.
health system with limited prescribing guardrails and prescriber over-
sight.13,14 Pharmacist education and training programs recognize these
needs and issues, as evidenced by innovative training programs.15,16
Further, pharmacies are part of the overall public health system,
especially in rural communities and in U.S. states such as Indiana,
where the public health infrastructure is not well funded17 and harm
reduction services are nascent.18
Our prior studies of Indiana managing pharmacists identified sev-
eral harm reduction-related service opportunities such as syringes sales
for nonprescription use,11 naloxone stocking and dispensing,12 and
PrEP (Pre-exposure prophylaxis for HIV prevention) consultation.19
These services are useful in isolation, but require further integration
within the pharmacy system, the overall healthcare system, and the
community – similar to much of the research on integrated care.20,21 At
the same time, such work would also benefit from an integration model
or framework that has been tested with opioid misuse.
Other research has investigated the utility of screening, brief in-
tervention, and referral to treatment (SBIRT) frameworks in mitigating
harm from opioid misuse in emergency departments (ED). Rather than
proposing a one-size-fits-all ‘SBIRT panacea;' 22 these approaches re-
cognize the general importance of risk identification, provision of a
service (be it counseling, medication, or advice), and either treatment
initiation or engagement with referral. Within this framework, we
highlight two recent randomized clinical trials in the ED. The first study
found fewer overdose risk behaviors and reduced non-medical opioid
use following a 30-min motivational interviewing (MI) session with
enhanced usual care in the ED (vs. enhanced usual care alone).23 The
second measured increased engagement in addiction treatment at 30
days and decreased self-reported illicit drug use following a brief ne-
gotiated interview, ED-initiated buprenorphine, and referral to primary
care for medical management, compared to ‘traditional’ SBIRT or basic
referral to opioid addiction treatment.24,25
In reviewing the interface between all of these studies, we con-
cluded that: (a) pharmacy practice is an important but often excluded
component of integrated care and harm reduction; (b) there are several
evidence-based services likely to benefit pharmacy patients but have
not yet been systematized, and (c) there is an extant, effective frame-
work for identifying risk, providing a service or medical device, and
facilitating entry into the medical treatment system.26
With this in mind, we designed a system-level pharmacy interven-
tion called PharmNet to reduce, among pharmacy patients, frequencies
of opioid overdose and misuse while reducing risk of hepatitis C (HCV)
and human immunodeficiency virus (HIV) infection and transmission as
an ancillary outcome of opioid injection. As a primary step in inter-
vention development, we conducted a study among all Indiana mana-
ging pharmacists at community pharmacies to assess the feasibility,
acceptability and likely adoption of this pharmacy-based harm reduc-
tion intervention. Findings from this study, shared herein, will inform
the evolution of PharmNet as we prepare for a pilot multi-site rando-
mized intervention trial in Indiana.
Methods
Data collection
A hybrid paper invitation and online census of Indiana community
managing pharmacists was conducted from July to October 2018. As
has been described elsewhere,27 a list of Indiana community pharma-
cies was obtained from Hayes Directories, Inc (Mission Viejo, CA) for
2018. This list provided the street address of all community pharmacies
in Indiana. Hospital, clinic-based, and compounding pharmacies were
removed from the list, along with pharmacies that had closed. The re-
sult was a list of 1,018 community pharmacies that composed our initial
sample. In reviewing the data for this study, an additional 34 phar-
macies were excluded, leaving the number of community pharmacies at
984. Pharmacies on the final list were located in 90 of Indiana's 92
counties. These pharmacies were then classified as one of four types of
community pharmacies: independent, chain (> 5 locations), food store
(pharmacies located in grocery stores), and mass merchandiser (phar-
macies located in stores that sell mass merchandise and are not pri-
marily pharmacies).
As the managing pharmacist is a singular role in every pharmacy,
we addressed a paper invitation letter to the ‘Managing Pharmacist’ for
each pharmacy. Survey invitations contained study information, a
$5.00 cash pre-incentive, a unique identifier, and a web address and QR
code that led to an online survey hosted in Qualtrics (Qualtrics
International, Inc.). The inclusion of the monetary pre-incentive had
precedent in our prior work with Indiana pharmacists.10,11
The initial invitation was followed by a second letter (without pre-
incentive) sent to non-respondents within 18 days of the first mailing.
Finally, up to two attempts for telephonic follow up were made with
those who had not completed the survey within 17 days of the second
mailing. The list of telephone numbers was generated by an internet
search for non-responding pharmacies. Calls were made by two phar-
macy students and one doctoral student. The study was deemed exempt
by the Indiana University Institutional Review Board.
Questionnaire
Survey items and their interpretation were selected and developed
to closely align with the Consolidated Framework for Implementation
Research (CFIR),28 as this survey would measure aspects of intervention
feasibility and acceptability. The CFIR is a multilevel implementation
framework informing several interventions in the past decade;29,30
though less so in the pharmacy practice sphere.31–34 To our knowledge,
there have been no pharmacy studies which assess intervention feasi-
bility and acceptability using the CFIR framework at the design stage.
The CFIR domains of interest and associated survey measures are found
in Table 1. As shown, we selected 25 constructs from the 5 CFIR do-
mains based on the ability to measure them at the implementation
planning stage; and therefore excluded those constructs measurable
only during implementation. Discussion with the research team, which
was comprised of implementation researchers, pharmacy research-
practitioners, and interventionists, resulted in the selection of the
constructs shown in Table 1. This approach is not unlike other studies
that attempt to select CFIR constructs for research in particular set-
tings.35
The survey questionnaire included quantitative and qualitative re-
sponse items. Quantitative response structures included selection lists
(e.g., “Please indicate whether your pharmacy has the following char-
acteristics: [select all that apply]”), Likert-type scales (e.g.,
“1= Strongly disagree; 5= Strongly agree”), rank ordering (“Rank the
PharmNet components by ease of delivery in your pharmacy by drag-
ging and dropping them in order. [Assume Rank #1 is the Easiest]”), and
forced choice (“In your current or past pharmacy work, have you used
validated screening tools to identify patient level of substance use,
anxiety, or similar health conditions? [Examples of these tools include the
Alcohol Use Disorders Identification Test {AUDIT-10} or the Generalized
Anxiety Disorder Scale {GAD-7}]”).
Pharmacist and pharmacy characteristics were measured, as well as
practice and beliefs related to PharmNet intervention components.
Pharmacists were also asked to indicate beliefs about community need
for PharmNet services. Survey items measuring pharmacist character-
istics, practice experience, continuing education, as well as their in-
teraction with patients and professionals in the past two years were
developed as part of our 2016 pharmacy survey, along with pharmacy-
level items related to naloxone and syringe access. That instrument was
repeatedly assessed for face validity by an interprofessional group of
experts, piloted internally and externally, and later administered as a
census.11,12 Questions were also selected and adapted from the online
resource CFIR Guide which listed several question options to be used in
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interviews to measure inner setting constructs of culture and im-
plementation climate.36 In addition, questions directly asking about
PharmNet components (screening, intervening, and referring) used
language drawn from established questions about performance of
SBIRT-related behaviors and modified in a face-valid manner.37 Three
open-ended survey response items followed a brief intervention de-
scription. They included pharmacists’ general opinions about the in-
tervention, alterations that needed to be made to improve feasibility,
and perspectives about how patients might respond to the intervention.
Finally, pharmacists were asked whether they were interested in ad-
vising the development of the PharmNet intervention. If so, they were
provided a separate means of conveying contact information to the
study team.
County-level covariates
Survey data were compared with county-level data related to
community need indicators for overdose and harm reduction services.
This was done to provide additional clarity about PharmNet feasibility,
particularly in areas of high need and low resources. These indicators
included: 1) number of organizations confirmed (telephonically by a
research team member) as distributing naloxone at no cost to lay-
persons,38 2) counties with syringe services programs39 that are con-
firmed as functioning,40 3) number of locations providing free or sliding
scale (cost) HIV testing services to the public as identified by the In-
diana state department of health,41 Planned Parenthood of Indiana and
Kentucky,42 and a county by county Google search by the research
team, 4) 2016 age-adjusted drug poisoning death rate for counties,
compared to the U.S. average (19.78 per 100,000 population),43 5) the
number of community pharmacies by county, and 6) Rural and Urban
Commuting Area (RUCA) designations44 calculated for each address
using the geomap tract locator.45 Categories were reduced for analysis
to: metropolitan, micropolitan, small town and rural designations. For
data point number four, the national average was selected over the state
average because Indiana had a skewed distribution of age-adjusted drug
poisoning death rates (few counties had very high rates). Two addi-
tional county-level indicators were derived from the questionnaire it-
self. These were: 1) number and percent of community pharmacies
dispensing syringes for non-prescription injection drug use, and 2)
number and percent of community pharmacies stocking naloxone.
PharmNet feasibility, acceptability and likely adoption
PharmNet is an adaptation of a Screening, Behavioral Intervention,
and Referral to Treatment model designed for delivery in the pharmacy
and based on prior formative studies by others10,33 and by members of
our research team.12,19,46,47 Our interdisciplinary research team
(pharmacy research and practice, SBIRT implementation, harm reduc-
tion interventions, and implementation scientists) designed the
PharmNet intervention model in November 2017. In the survey, we
described the intervention to participants prior to soliciting their
feedback as follows (verbatim):
PharmNet has 3 components:
Screening for opioid misuse and addiction - Patients can in-
dependently and privately complete screening questions within
15min using a handheld device containing questions from PainCas
[™(Inflexxion, Inc Newton, MA)], a scientifically validated web-
based clinical tool for assessing pain and opioid misuse risk.48 This
can be privately completed in the pharmacy waiting area in 15min,
during which the pharmacy serves other patients.
Brief Intervention using Motivational Interviewing focused on the
outcome of the screening: A conversation lasting no more than
15min designed to reduce patient ambivalence about - as necessary
- accessing addiction treatment, reducing opioid use, use of na-
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Referral to Treatment at local or nearby service providers in the
community in cases where it is indicated: At a minimum, a written
referral to addiction treatment and/or additional health screening
such as for HIV or hepatitis C (the PharmNet research team will
assist with identifying local agencies for referral). If time permits,
utilize a ‘warm handoff’ such as a three-way phone call to introduce
the patient to the referred provider.
We will work with pharmacies to develop a question to identify
patients who might benefit from this intervention in order to
ensure patient comfort and reduce environmental bias.
The CFIR domains and constructs allowed the organization of con-
cepts related to PharmNet feasibility, acceptability and likely adoption.
Analyses involved description of quantitative survey items focused on
intervention feasibility, acceptability and likely adoption; and their
triangulation with analyzed qualitative data in cases where qualitative
themes aligned with quantitative subject matter. Qualitative data were
approached with open coding following the organization of data into
the following a priori CFIR constructs: acceptability (attitudes about the
intervention and likely patient response to it), feasibility (changes
needed to improve feasibility), and cost (likely patient response to
PharmNet). Qualitative rigor was achieved through a congruency
analysis conducted at the time of data translation (the extent to which
qualitative themes reflected quantitative responses by those offering
both),49 the fact that qualifications and background of the investigators
reflected those being studied,50 and through the adoption of credible
Table 2
Community managing pharmacist and pharmacy characteristics, Indiana 2018 (N=303).
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research procedures.51 Congruency between qualitative and quantita-
tive survey data was observed (no conflicts), the research procedures
used here were used in our prior survey studies among this popula-
tion,11,12 and the research team composition reflected pharmacy-based
research and practice, survey research and qualitative analysis.
Comparison of feasibility measures with pharmacy, pharmacist and
community characteristics was accomplished through bivariate Pearson
goodness of fit, chi-square testing, and analysis of variance. Because
these were exploratory analyses only, we did not apply a correction to
significance levels for multiple comparisons (e.g., Bonferroni). This is
because significance adjustments are designed to control for group-
wide type one error,52 whereas these tests are not assessing a shared
hypothesis but rather indicating areas of potential interest in numerous
domains toward which it might be prudent to place attention during
implementation. SPSS (v.25) and QSR NVIVO (v.12) were used to or-
ganize and analyze data. Qualitative comments are reported with
quantitative responses to provide additional clarity.
Results
Complete survey responses were received from 303 Indiana mana-
ging pharmacists for a response rate of 30.8%. Of this group, 70.9%
(215) responded to at least one open-ended survey item. Those re-
sponding with written comments did not vary by pharmacy type, rur-
ality, or county age-adjusted drug poisoning death rate from those that
did not provide written comment. All responding pharmacists worked
in 74 (82.2%) of Indiana's 90 counties that had community pharmacies.
Of the 16 counties with no responding pharmacists, half had no more
than 2 pharmacies (5 of which had only 1 pharmacy).
Pharmacy characteristics
The sample included 37.3% chain, 24.8% food store, 22.8% in-
dependent, and 15.2% mass merchandiser pharmacies. This partially
reflected Indiana's distribution of community pharmacy types. As
compared to the sample's distribution of pharmacies by type, Indiana
had a lower percentage of independent and food store pharmacies
(13.3% and 13.6% respectively) and a higher percentage of chain and
mass merchandiser pharmacies (53.2% and 19.9% respectively). The
gender and race/ethnicity distribution of responding managing phar-
macists reflected Indiana's pharmacist population according to the
Indiana 2012 workforce report (latest available).53 Pharmacy, phar-
macist, and community characteristics are found in Table 2.
Staffing levels varied by pharmacy type: the mean number of full
time, non-floating pharmacists at chain pharmacies and mass mer-
chandisers were 2.3 and 2.2, respectively, whereas for independent and
food store they were 1.6 and 1.9, respectively (F=9.0, df=3,
p≤ .05). Mass merchandisers had a larger mean number of floating
pharmacists (1.1) compared with 0.6 each at chain, food store, and
independent pharmacies (F=3.2, df=3, p≤ .05). Over half (54.1%)
of pharmacies had overlap pharmacy staffing. While metropolitan area
respondents comprised a majority each pharmacy type, pharmacists
from rural areas worked primarily in chain and independent pharma-
cies (X2=11.4 [chain], X2=31.9 [independent], df=8, p≤ .05).
PharmNet feasibility, acceptability and likely adoption
Indicators of PharmNet feasibility, acceptability and likely adoption
are arrayed by CFIR domain and construct in Table 3. This table also
classifies responses as implementation facilitators or barriers. Associa-
tion with county-level variables (pharmacy type, community rurality,
or age-adjusted drug poisoning death rate) was tested for each identi-
fied barrier and facilitator but is reported only when exceeding baseline




The CFIR construct of relative advantage is an acceptability indicator
referring to perceptions about the benefit or burden to pharmacy pa-
tients. There appeared to be a bifocal view of PharmNet's burden and
benefit to patients; in that a majority of pharmacists (83.3%) agreed or
strongly agreed that their patients would benefit from the PharmNet
intervention, though this belief was less common among rural pharma-
cists (77.8% [small town], 94.2% [micropolitan], 83.2% [metropolitan],
vs. 60% [rural], X2=9.1, df=3, p < .05). In stark contrast was the
opposing (and simultaneously held) view that patients might feel bur-
dened by the intervention process (83.3%). Pharmacists providing
written explanations indicated that stigma and the conflict with pre-
scribing behavior might influence patient receptivity to PharmNet.
If the patients approached us for the intervention, I assume they would be
pleased with the service. However, if we approached them and mis-
identified them as a candidate for a screening this could result negatively.
(Respondent 153)
It would be a tough change because doctors make patients think that pain
pills are the only pain management solution in our area. Other options
seem to be rarely explored. (Respondent 175)
Pharmacists also indicated that negative customer response to
PharmNet might be linked with customer expectations about time spent
in the pharmacy.
I'm not sure what changes could be made [to the intervention]. With the
drive-thru mentality, patients are not open to some interventions and the
time that it takes to complete them. (Respondent 126)
I suspect that most who use opiates will not like the intervention as there
is a whole lot more to the intervention …. .We get yelled at and com-
plained on already holding patients to the 2 day early refill and the in-
surance 7 day acute opiate rules. (Respondent 254)
Cost
Cost was deemed an indicator of feasibility and likely adoption
because it refers to the cost of implementing the intervention to the
pharmacy and staff. Findings related to cost were closely linked with
inner setting characteristics due to the structure and financing of
pharmacy practice (see inner setting below). When pharmacists con-
sidered the cost of implementing PharmNet components, 75.7% be-
lieved that PharmNet, or key components of it, should be reimbursed.
This was particularly the case for the brief intervention focused on
screening outcomes (69.8%), which (by design) would require phar-
macist time. Cost associated with PharmNet was primarily con-
ceptualized as pharmacy staffing costs.
Adaptability and complexity
The measures related to constructs of adaptability and complexity
indicated pharmacist perceptions of PharmNet feasibility, acceptability
and likely adoption. In terms of PharmNet's implementation complexity,
70.0% of pharmacists felt that with adequate training, their pharmacy
staff could deliver PharmNet services. Thirty-eight percent of pharma-
cists believed PharmNet had a design similar to other pharmacy inter-
ventions focused on screening and behavior modifications, and 65.7%
who held this view reported prior experience with these types of inter-
ventions. At the same time, 24.0% of pharmacists believed that
PharmNet was too complicated for delivery at their pharmacy. This did
not vary by perceptions of PharmNet's similarity to other pharmacy in-
terventions or reported experience with screening or brief interventions.
To further understand adaptability, complexity, and likely adoption,
we asked pharmacists to rank each of the PharmNet components by
ease of delivery in their current pharmacy; and 87.8% of pharmacists
responded (N=266) with rankings (data not shown). Almost 60% of
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pharmacists rated ‘Patient Identification’, ‘Dispensing Naloxone’, and
‘Dispensing Syringes’ as relatively easy by giving them a rank of 3 or
lower in the 7-point semantic differential scale (1= easiest,
7= hardest). Further, 71% of pharmacists rated ‘Delivering Brief
Intervention’ as relatively difficult by giving it a rank of 5 or higher.
Reasons for this are unknown; however, as previously noted, it was this
component of the intervention that was perceived as most costly in
terms of pharmacist time. Pharmacists also rated ‘Providing the
Referrals’ (55%) and ‘Reviewing the screening score and identifying
brief intervention focus’ (53%) as relatively difficult.
Table 3
PharmNet acceptability, feasibility and likely adoption by Indiana pharmacists, 2018 (N=303).
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Inner setting: pharmacy culture, structure, and implementation climate
Inner setting characteristics refer to measures of implementation
feasibility, acceptability, and likely adoption. When asked general
questions about the pharmacy environment, most pharmacists (77.2%)
believed their pharmacy's culture supported practice change, and that
pharmacy leadership supported new ideas to improve patient health
(79.2%). When asked specifically about PharmNet, 20.5% of pharma-
cists indicated that pharmacy leadership would not support the practice
change suggested by PharmNet, and 50.0% of those pharmacists were
working in chain pharmacies (X2=12.2, df=4, p≤= .05).
Pharmacy practice culture and the structure of work were noted by
pharmacists as they responded to questions about the intervention and its
‘fit’ in the pharmacy environment. Despite the predominance of conceptual
support for PharmNet, 48.2% of pharmacists felt that their pharmacy did
not have time for a type of intervention like PharmNet. This belief was
held at 57.5% of chain pharmacies (X2=6.2, df=1, p≤.01), but fewer
than half (33.3%) of independent pharmacies (X2=7.9, df=1, p≤.01).
Time was also noted in the written comments, where pharmacists de-
scribed the current pharmacy practice environment as extremely busy and
pressured with budget and staffing cuts, 19.5%, (42) indicated that owner/
corporate control limited what could be implemented in pharmacies.
Increased prescription numbers with drastic pharmacist hour cuts and
corporate pressures on clinical interventions required to garner DIR
[Direct and Indirect Remuneration] fees greatly reduce time for any
additional services. (Respondent 107)
With high script volumes, reduced labor hours, and more and more re-
sponsibilities being placed at community pharmacies, it is very difficult to
find time to do these interventions ……(We need to be) burdened with less
work so that interventions can take place. We need to be less of an as-
sembly line and be treated like medical professionals. (Respondent 15)
Outer Setting
Patient needs and resources, patient expectations, external policies and
incentives
Pharmacists reported whether, in the past 2 years, they had been
asked about aspects related to harm reduction services in the pharmacy
by patients, other pharmacists, or medical providers. These measures
served as indicators of patient needs and expectations, as did reported
pharmacist perception of opioid misuse in the community. Nearly all
(97.7%) pharmacists had been asked by patients about one or more
syringe-related issue (sharps disposal, sale of syringes, and return of un-
used syringes), and 80.2% had been asked about naloxone access
through insurance, at cost, at reduced cost or for free. Pharmacists
working for chains were more likely than other pharmacists to report
that patients asked about naloxone at reduced cost or for free (X2=8.6,
df=1, p≤.01). Chain (74.8%, x2=7.0, df=1, p≤.01) and food store
pharmacists (50.7%, X2=7.7, df=1, p=. p≤.01) were more likely to
report that patients asked about return or donation of unused syringes.
Table 4
Indiana pharmacist experience and comfort with PharmNet-Like intervention components, Indiana (N=303).
Pharmacist Has Done so
Personally
Other Pharmacists at this
Pharmacy have done this
Technicians at this Pharmacy
have done this
#(%) #(%) #(%)
Screening in Current or Past Practice
Used validated screening tools to identify patient level of substance use,
anxiety, or similar health conditions.
34 (11.2%)
Behavioral and Test Consultations In Past Two Years
Had experience with briefly intervening with patients to reduce
possible harm from substance use, anxiety, or similar health
conditions.
164 (53.8%)
Provided behavior modification consultation about condom use 46 (15.2%) 21 (6.9%) 4 (1.3%)
Provided behavior modification consultation about safe syringe use 107 (35.3%) 40 (13.2%) 7 (2.3%)
Provided behavior modification consultation about prescribed opioid
use reduction
223 (73.6%) 116 (38.3%) 8 (2.6%)
Provided behavior modification consultation focused on Illicit opioid
use reduction
100 (33.0%) 42 (13.9%) 1 (0.3%)
Consulted about HIV test results 9 (3.0%) 7 (2.3%) 2 (0.7%)
Pharmacy Practice at Current Pharmacy
Dispensed naloxone 215 (71.0%) 121 (39.9%) 10 (3.3%)
Dispensed naloxone that was free or subsidized 54 (17.8%) 40 (13.2%) 4 (1.3%)
Dispensed syringes to patients for likely injection drug use 89 (29.4%) 64 (21.1%) 32 (10.6%)
Provided education about naloxone 230 (75.9%) 125 (41.3%) 13 (4.3%)
Provided education about naloxone administration 203 (67.0%) 122 (40.3%) 4 (1.3%)
Educated about safe syringe disposal 218 (71.9%) 121 (39.9%) 30 (9.9%)
Referrals to Services
Provided referrals for addictions treatment 44 (14.5%) 14 (4.6%) 3 (1.0%)
Provided referrals for HIV testing 20 (6.6%) 12 (4.0%) 3 (1.0%)
Provided referrals for Hepatitis C testing 14 (4.6%) 8 (2.6%) 2 (0.7%)
Provided referrals for HIV treatment 8 (2.6%) 11 (3.6%) 1 (0.3%)
Provided referrals for Hepatitis C treatment 8 (2.6%) 8 (2.6%) 1 (0.3%)
Comfort Consulting about Personally Comfortable
Safe syringe use 273 (90.1%)
Safe syringe disposal 285 (94.1%)
The need for naloxone 253 (83.5%)
Reducing opioid misuse 225 (74.3%)
Safer sex practices 196 (64.7%)
Comfort Dispensing
Naloxone for overdose reversal 255 (84.2%)
Referrals for community services 225 (74.3%)
Syringes to patients for likely injection drug use 110 (36.3%)
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Less than 15.0% of pharmacists reported that patients asked about
screening for addiction, HIV and/or hepatitis C, or treatment for ad-
diction, HIV, or hepatitis C; however, 86.0% and 90.3% of pharmacists
asked by patients about HIV testing or addiction screening (respec-
tively) were also asked about the sale of syringes for non-prescription
injection drug use (X2=7.7, df=1, p≤ .01 and X2=8.1, df=1,
p≤ .01 respectively). In counties with higher drug poisoning death
rates, 78.4% of pharmacists reported that they had been asked by pa-
tients about sale of syringes for non-prescription injection drug use,
compared to 63.3% of pharmacists in other counties (χ2=6.55, df=1,
p=0.01).
Most pharmacists (79.5%) believed that pharmacies should offer
new services to help reduce opioid addiction and overdose among their
patients. This belief was more likely held by those who believed that
opioid abuse was either a “community emergency” or a “major pro-
blem” in the community (X2=26.3, df=4, p≤ .001), and that there
was a need for additional addiction and overdose risk screening in the
community (X2=74.3, df=6, p≤ .001).
Characteristics of individuals
The CFIR domain of ‘Characteristics of Individuals’ refers to per-
ceptions held by individuals regarding self-efficacy for implementing
intervention aspects, and perceptions about the implementing organi-
zation. This domain was measured through perceived control over the
implementation environment, experience with PharmNet-like elements,
and comfort delivering them. Table 4 reports pharmacy staff experience
and comfort with several PharmNet-like components.
While only 35.3% of pharmacists reported providing behavioral
consultation about safe syringe use in the past 2 years, most pharma-
cists (90.1%) reported being comfortable with this pharmacy practice.
However, less than half of pharmacists (36.3%) were comfortable dis-
pensing non-prescription syringes for likely illicit drug injection, and
only 29.4% had actually dispensed in this circumstance. Independent
pharmacists were less likely than other pharmacists to report that they
had dispensed non-prescription syringes for likely injection drug use
(15.9%, X2= 12.8, df= 1, p≤ .001).
Large majorities of pharmacists were comfortable consulting about
the need for naloxone (83.5%) and dispensing naloxone for overdose
reversal (84.2%). The latter group included more independent phar-
macists (71.0%, X2=10.1, df= 2, p≤ .01) and mass merchandiser
pharmacists (95.7%, X2=6.0, df= 2, p≤ .05) than other types of
pharmacists. Consultation about the reduction of opioid misuse was
more fragmented, as 74.3% of pharmacists reported being comfortable
consulting with patients about opioid misuse reduction, but, in the past
2 years, only 33.0% had provided such counseling. Further, only 14.5%
of pharmacists reported having provided referrals for addiction treat-
ment, a group of which nearly half (43.2%) were independent phar-
macists (X2=13.4, df=3, p≤ .01).
Over half (62.4%) of pharmacists believed that PharmNet was
within pharmacy scope of practice. That said, pharmacist comments
about the structural aspects of the practice environment reflected per-
ceived lack of control over what happened in the pharmacy.
Nothing (about PharmNet) would need to be altered for it to be more
acceptable to the pharmacy staff. The culture within retail pharmacy
needs to be altered. Large pharmacy corporations are focused on saving
dollars by payroll reductions. As pharmacists we simply would not have
the time during a normal day to complete the screenings and assessments.
(Respondent 138)
Corporate office continues to add extra steps, reports, additional im-
munizations and metrics we cannot reach with allotted staffing cuts- not
sure how we could add more. Although I do feel this service is much more
beneficial to those we serve rather than harassing our patients to see if
they need sildenafil refilled. (Respondent 260)
Process
The study was conducted to inform intervention implementation
planning, which is part of the domain “Process.” Other characteristics
related to Process involved activities after implementation or as im-
plementation begins. This includes engaging appropriate persons in the
implementation process, the process of intervention execution, and the
process of reflecting while in the midst of the intervention. The entire
feasibility study was a step toward the Planning characteristic, so as to
assure the advance development of the intervention as informed by
implementing individuals and organizations. We also measured interest
in continued planning engagement prior to implementation by asking
pharmacists whether they and/or their staff might be interested in
advising the continued development of PharmNet. Over one third
(38.0%) of pharmacists indicated interest in advising the development
of PharmNet. Of those, 82.6% believed that with training their staff
could implement PharmNet or similar services (X2=19.2, df=4,
p≤ .001).
Discussion
This study was among the first to use the CFIR framework at the
development phase of a pharmacy-based intervention. This use of the
CFIR framework allowed the characterization of multilevel aspects of
intervention implementation at the planning stage so that the resulting
intervention more precisely reflects the implementing environment,
and will hopefully mitigate adoption issues. While CFIR's measures are
intentionally not optimized to summarize objective intervention feasi-
bility, implementation researchers are able to surmise feasibility in
context.
Based on reported pharmacist perceptions about intervention
characteristics (complexity, cost, relative advantage and adaptability)
and based on characteristics of individuals (experience with similar
interventions and perceived comfort with intervention elements), we
have concluded that the important components of PharmNet appear
generally feasible but will need to be modified to facilitate intervention
adoption. These modifications retain the core structure designed to
screen, intervene, and refer; yet streamline the procedures to minimize
both client and pharmacist burden, as outlined later in this section.
From the standpoint of intervention characteristics, there was
widespread belief that PharmNet would benefit patients and, with
adequate training, could be implemented. A majority of pharmacists
had experience and were comfortable with key aspects of PharmNet,
such as consulting about safe syringe use, need for naloxone and opioid
misuse reduction. Most pharmacists also believed their pharmacy cul-
ture supported practice change, leadership supported ideas to improve
patient health, and that their pharmacies ‘sometimes’ implemented new
programs to improve patient health. Finally, many pharmacists be-
lieved there was a need for additional addiction and overdose risk
screening in the community and that pharmacies should offer new
services to address these risks among their patients.
These findings are consistent with other pharmacy studies that have
examined, in isolation, one or more proposed components of PharmNet.
Cochran et al. found that community pharmacy screening in two
Pennsylvania community pharmacies for prescription opioid misuse
was feasible,54 as did Strand et al.'s implementation study of a pre-
scription opioid misuse screening toolkit among 11 North Dakota
pharmacists.4 Hagemeier et al.'s study of factors associated with Ten-
nessee pharmacist provision of treatment information to patients found
that pharmacist characteristics, as well as having information about
treatment facilities located within the pharmacy, were associated with
reported provision of addiction treatment information to patients.55
At the same time, supportive pharmacist beliefs about PharmNet
benefits, adaptability, and feasibility should be balanced by concerns
that PharmNet might burden both pharmacists and patients. Qualitative
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feedback revealed that some pharmacists viewed their burden as part-
ners in the healthcare relationship as disproportionate or inappropriate
relative to their compensation. This is especially salient with regard to
reported perceptions that current pharmacy environments function like
“drive-thrus.” This has implication for pharmacist workload and patient
expectation; and may also influence the types of interventions possible
in the pharmacy environment. Flemming et al.'s small study of Texas
pharmacists highlighted this conflict. They reported the belief that
engaging patients about prescription drug misuse might cause a loss of
business, despite perceived benefits to patients.7 Whether general per-
ceptions of potential patient burden were due to beliefs about patient
service expectations or other reasons was not clear.
Concerns of time constraints and lack of leadership support for
PharmNet implementation were expressed particularly by pharmacists
working in chain pharmacies. This is notable because chain pharmacists
tended to report more often than their other pharmacy peers that pa-
tients asked about opioid screening, naloxone access at free or reduced
cost, and syringes for non-prescription injection drug use. Being a chain
pharmacy was also positively associated with naloxone stocking in our
2016 survey of Indiana managing pharmacists, at a time when fewer
than 60% of Indiana community pharmacies did so.11 This finding re-
inforces the importance of seeking leadership support above the
managing pharmacist level prior to PharmNet implementation.
Study findings led us to alter the PharmNet intervention in several
ways. Pharmacist reported lack of control over workflow underscores
the challenge of integrating new interventions in the pharmacy setting.
This reflects similar concerns expressed by managers and frontline
workers in primary care.56 Based on survey feedback, we learned that
our initial screening proposal was overly ambitious given current
pharmacy workflow. This study leads us to propose, instead, the use of
electronic self-administration (by the client) of the 10-question Opioid
Risk Tool (ORT).57 This was developed in 2005 to identify risk among
patients prescribed opioids for chronic pain. It was re-validated in
2019, reduced by one item, and response weighting was removed in
order to obtain stronger predictive validity.58 The National Institute on
Drug Abuse notes that the original 10-question tool can be administered
and scored in fewer than 60 seconds.59 It is far more likely that this tool
can be inserted into pharmacy workflow while retaining client privacy.
Second, the extant pharmacy system may not support even ‘brief’
(15-min) consultation with clients in many cases, though a reasonable
percentage of pharmacists reported having done so at least once. This
does not affect the conceptual goal of the ‘Brief Intervention.’ A driving
principle of SBIRT is the appropriate pairing of identified need (via
screening) to the service. The screening tool identifies risk from opioids,
and in the pharmacy environment, we are particularly interested in
harm reduction services – provision of naloxone and clean syringes – as
a first-line response for at-risk individuals. We therefore plan to replace
the ‘BI’ component with ‘Service Provision.’ Replacing the motivational
interview-based BI with an alternative interaction has precedent with
recent successful ‘STIRT’ work in emergency departments.24,25 How-
ever, patients may be ambivalent about accessing those resources
(especially at cost), and pharmacists may not feel equipped to have
those conversations. We therefore still feel that some level of Motiva-
tional Interviewing training is warranted to facilitate the negotiation
around Service Provision. That training can also be used in larger time
increments, when feasible and clinically appropriate, to address ad-
diction treatment access, reductions in opioid use, or other pertinent
consultation topics. However, the consultation is no longer the pro-
posed emphasis of the Service Provision component of the intervention.
Third, while the ‘Referral to Treatment’ component was not sub-
stantially influenced by our findings, study findings reinforced the
importance of providing pharmacies with resources to facilitate re-
ferral, including documentation, maps, lists, and even – perhaps –
sponsored in-person introductions to facilities nearby the pharmacy to
drive interprofessional connectedness.
One encouraging finding was the number of pharmacists
volunteering to advise the development of the PharmNet intervention.
This indicates continued interest in co-developing an evidence-based
intervention that will have higher likelihood of adoption and adapta-
tion in pharmacy settings. It also provides a larger group of advisors
that will help to address larger structural questions ahead, such as re-
muneration and access to subsidized naloxone for lay persons.
Limitations
This study had a few limitations. First, there was a clear conflict
between two disparate but widely held beliefs: that PharmNet would
benefit patients and that it would burden them. We were unable to
understand the meaning of these simultaneously held, yet conflicting
beliefs. Additional exploratory research among pharmacists will hope-
fully yield helpful information.
Second, support for PharmNet in rural areas was lower; yet, the size
of the rural subsample (n= 10) was not enough to determine whether
the 40% of rural pharmacists who felt that PharmNet would not benefit
patients was representative of all rural pharmacists in Indiana. Future
studies among rural pharmacists would provide additional guidance
about the pharmacy practice environments in rural communities,
especially given the role rural pharmacies play in the health of com-
munities.
Finally, we could not fully understand the structural environment
and how it serves as a barrier to PharmNet adoption and implementa-
tion. The conflict between pharmacy practice environments and phar-
macist beliefs about patient need is beyond the scope of this study;
however, it is important to address if pharmacy-based interventions – of
any kind - are to succeed. For example, PharmNet may be more likely to
succeed if the structural barrier of service remuneration is addressed.
Creating the possibility for reimbursement for screening and service
provision might mitigate the economic model that many pharmacists
noted- where prescriptions filled was the primary business value of the
pharmacy to pharmacy owners. Moving forward with this aspect will
require collective effort, as noted by Bernsten et al.,'s 2010 interna-
tional review of pharmacy remuneration models.60 That said, there is
little conversation about this point in the literature. Wazaify et al.'s
small study of Northern Ireland pharmacists indicated support for and
implementation success of motivational interviewing (MI) to reduce
patient over-the-counter drug misuse without discussion of remunera-
tion.61 Ahmad et al.'s study of MI and problem solving treatment (PST)
by pharmacists during medication review among post hospitalized el-
derly patients also did not address funding for the additional service of
MI or PST, nor have findings been published to our knowledge.62 Fi-
nally, Lonie et al.'s discussion of MI and even health coaching did not
address pharmacist remuneration.63
That said, while a majority of pharmacists believed there should be
remuneration for aspects of PharmNet's intervention, most did not state
the lack of it as a barrier. It is possible that a PharmNet intervention
trial should attempt to gather evidence of time spent and cost incurred
in order to share with policy partners the program's financial value.
However, grantmakers simply cannot handle all implementation costs
initially, particularly if naloxone is provided to patients who do not
have insurance and need assistance procuring it at out-of-pocket rates.
Negotiating with state governments who have access to free or sub-
sidized naloxone for laypersons may be a solution.
Conclusions
An integrated intervention to reduce opioid overdose and related
health concerns (e.g., HIV and HCV infection) in an at-risk population is
likely acceptable and feasible in community pharmacies, particularly if
development includes an implementation process that engages im-
plementers themselves and attends to identified implementation bar-
riers.
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